OA
QNCX icon

Operose Advisors’s Quince Therapeutics QNCX Stock Holding History

Operose Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89K Buy
+159
New +$3.65K ﹤0.01% 451
2026
Q1 		– Sell
-158
Closed -$106K – 640
2025
Q4 		$106K Hold
158
– – 0.02% 209
2025
Q3 		$51.5K Buy
+158
New +$52.6K 0.01% 255

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Operose Advisors's QNCX Position: Q2 2026 in Review

Operose Advisors opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 159 shares worth $2.89K. The stake represents ﹤0.01% of the portfolio and ranks #451 among its holdings. This is a return to the name: Operose Advisors previously reported a position in QNCX as recently as Q4 2025.

Operose Advisors first reported a position in QNCX in Q3 2025 and has held it in 3 quarters since. The position peaked at $106K in Q4 2025. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Operose Advisors held 159 shares of Quince Therapeutics worth $2.89K as of Q2 2026.
  • Quince Therapeutics was a new Operose Advisors position in Q2 2026.
  • Quince Therapeutics made up ﹤0.01% of Operose Advisors's portfolio in Q2 2026, its #451 holding.
  • Operose Advisors first reported a position in Quince Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Operose Advisors's Quince Therapeutics position peaked at $106K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.